An extended release formulation breaks through by Chael Needle Based on results from the VERxVE study, the FDA recently approved Viramune XR for use in antiretroviral combination therapy to treat HIV-1 infection in adults. “XR” stands for “extended release,” offering patients a one 400mg pill, once-daily dosing option. Until now, Boehringer Ingelheim, makers of Viramune (nevirapine), had offered an immediate-release (IR), 200mg form of the drug with a twice-daily dosing. “Development of the extended-release formulation began in 2004 to provide a once-a-day preparation that was [...]